22 results
Thumbnail

- D1.536 - Immunological basis of coexisting slowly progressive insulin-dependent diabetes mellitus (SPIDDM) and Vogt–Koyanagi–Harada disease (VKH)

Thumbnail

- D1.537 - Immunopharmacogenomics as a Systems Medicine Framework for Precision Therapy in Allergic and Immune Mediated Diseases

Thumbnail

- D1.538 - First Report of the SERPING1 c.52-1G>A Variant in a Chinese HAE Pedigree: Severe Abdominal Phenotype Correlated with Attack-Phase Imaging

Thumbnail

- D1.540 - Automated generation of real-world clinical databases in Allergy: a data-driven research framework

Thumbnail

- D1.541 - Addressing Allergy undergraduate education: Strategic Reforms for Specialist-Led Allergy teaching in Medical Curricula. A EAACI Tailored Education Committee Task Force

Thumbnail

D2.283 - Efficacy and safety of remibrutinib in adults with IgE-mediated peanut allergy: A Phase 2 study

Thumbnail

D2.286 - High Prevalence of Clinical Tolerance to Avoided Foods in LTP-Sensitized Patients

Thumbnail

D2.287 - Clinical characterization and predictors of diagnosis and severity in sunflower seed allergy in a pediatric population

Thumbnail

D2.276 - Clinical and Immunological Differences in Shellfish Allergy

Thumbnail

D2.278 - Dose-response analysis of remibrutinib in oral food challenge outcomes among adults with IgE-mediated peanut allergy

Thumbnail

D2.280 - Biphasic anaphylaxis due to psyllium (Plantago ovata) allergy, the primary component of a plant-based sausage

Thumbnail

D2.281 - Ensemble Immunoinformatic Prediction Reveals Novel Allergen Candidates in Nigella sativa Seeds and Oil

Thumbnail

D2.284 - Peanut Materials Used for Immunoassay Calibration Exhibit Distinct Allergen Profiles

Thumbnail

D2.285 - Baked egg oral Immunotherapy as an alternative in patients who failed raw egg oral immunotherapy

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child